Medroxyprogesterone Acetate (DB00603): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Medroxyprogesterone Acetate (MPA), a synthetic derivative of progesterone, is a small molecule drug with a long and complex history in clinical medicine. As a potent progestin, its primary utility lies in its ability to modulate the female reproductive cycle and oppose the effects of estrogen, leading to a broad therapeutic portfolio that encompasses long-acting contraception, menopausal hormone therapy (MHT), the management of various gynecological disorders, and palliative care in oncology.[1] However, the clinical application of MPA is defined by a critical and continuously evolving balance between its therapeutic efficacy and a significant, multifaceted safety profile.

The drug's primary mechanism involves potent agonism at the progesterone receptor, leading to the inhibition of gonadotropin secretion and subsequent anovulation, which forms the basis of its highly effective contraceptive action, most notably in its depot injectable formulations (Depo-Provera).[3] In MHT, it serves a crucial role in preventing estrogen-induced endometrial hyperplasia in non-hysterectomized women.[1] Its utility extends to treating endometriosis, abnormal uterine bleeding, and certain hormone-sensitive cancers, as well as niche applications in managing paraphilia and cancer-associated cachexia.[1]

This therapeutic versatility is counterbalanced by substantial risks, which are highlighted by multiple U.S. Food and Drug Administration (FDA) Boxed Warnings. For its injectable contraceptive forms, the most prominent warning concerns the potential for significant and possibly irreversible loss of bone mineral density (BMD) with long-term use, a critical consideration, particularly in adolescents.[9] When used in combination with estrogens for MHT, MPA is associated with increased risks of cardiovascular disorders (including stroke and venous thromboembolism), invasive breast cancer, and probable dementia in women over 65, as established by the landmark Women's Health Initiative (WHI) study.[12]

Furthermore, the safety profile of MPA continues to evolve. Recent epidemiological evidence, emerging prominently in 2024, has established a strong, duration-dependent association between prolonged use of injectable MPA and a significantly increased risk of developing intracranial meningioma, a finding that has prompted new warnings and contraindications from regulatory bodies such as the European Medicines Agency (EMA).[15] Pharmacologically, MPA is distinct from natural progesterone due to its additional weak glucocorticoid and androgenic activities. Its interaction with the glucocorticoid receptor, in particular, is believed to mediate unique immunosuppressive effects that may influence susceptibility to infections and contribute to some of its metabolic side effects, further complicating its risk-benefit assessment.[18] This monograph provides an exhaustive analysis of Medroxyprogesterone Acetate, synthesizing its chemical properties, pharmacological profile, clinical applications, and comprehensive safety data to inform judicious and evidence-based clinical practice.

Chemical Identity and Physicochemical Properties

The precise identification and characterization of a pharmaceutical agent's physical and chemical properties are fundamental to understanding its formulation, pharmacokinetics, and biological activity. Medroxyprogesterone Acetate is a well-characterized synthetic steroid derivative of progesterone.

Systematic Identification

Medroxyprogesterone Acetate is known by numerous synonyms and is cataloged in major chemical and pharmacological databases under specific identifiers. Its systematic nomenclature according to the International Union of Pure and Applied Chemistry (IUPAC) and other key registry numbers provide an unambiguous chemical identity. These identifiers are crucial for regulatory submissions, scientific literature searches, and accurate compounding.

Table 1: Chemical and Drug Identifiers for Medroxyprogesterone Acetate

Identifier Type	Value	Source(s)
IUPAC Name	phenanthren-17-yl] acetate	1
Common Names	Medroxyprogesterone acetate (MPA), Depot medroxyprogesterone acetate (DMPA)	1
CAS Number	71-58-9	20
DrugBank ID	DB00603	20
PubChem CID	6279	1
Molecular Formula	C24​H34​O4​	20
Molecular Weight	386.52 g/mol	22
InChIKey	PSGAAPLEWMOORI-PEINSRQWSA-N	20
Canonical SMILES	C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C	20
UNII	C2QI4IOI2G	20
EC Number	200-757-9	20

Physical and Chemical Characteristics

Medroxyprogesterone Acetate exists as an odorless, white to off-white microcrystalline powder.[20] It is described as being stable in air.[23] The reported melting point range is consistently between 200°C and 210°C, with specific literature values citing 206-207°C.[22]

The solubility profile of MPA is a defining characteristic that directly influences its pharmaceutical formulation and pharmacokinetic behavior. It is practically insoluble in water but exhibits solubility in various organic solvents. It is freely soluble in chloroform, soluble in acetone and dioxane, sparingly soluble in alcohol and methanol, and slightly soluble in ether.[14]

The inherent lipophilicity of the steroid structure and its poor aqueous solubility are the primary drivers of its pharmacokinetic profile, particularly for parenteral formulations. Because it cannot be administered as a simple aqueous solution, it is formulated as a sterile aqueous microcrystalline suspension for intramuscular (IM) or subcutaneous (SC) injection.[1] Upon injection, these microcrystals form a drug reservoir, or "depot," within the muscle or adipose tissue. The drug then dissolves slowly from this depot into the systemic circulation over an extended period. This slow dissolution process is the direct physicochemical mechanism responsible for its long-acting therapeutic effect, allowing for dosing intervals of several months for contraception, and explains the markedly prolonged apparent half-life of parenteral formulations (approximately 50 days) compared to the much shorter half-life of oral tablets (12–33 hours).[1] This fundamental link between the molecule's chemical nature and its most prominent clinical application underscores the importance of physicochemical properties in drug design and delivery.

Comprehensive Pharmacological Profile

The pharmacological activity of Medroxyprogesterone Acetate is complex, characterized by a primary, potent effect on the progesterone receptor, supplemented by secondary activities at other steroid hormone receptors. This profile explains both its wide range of therapeutic applications and its distinct side effect profile.

Mechanism of Action

[Primary Progestogenic Activity]

Medroxyprogesterone Acetate is a synthetic progestogen, a class of drugs that mimic the effects of the endogenous hormone progesterone. Its principal mechanism of action is as a potent agonist at the progesterone receptor (PR).[1] The therapeutic effects of MPA, particularly in contraception and gynecology, are a direct consequence of this receptor activation in key tissues of the hypothalamic-pituitary-gonadal (HPG) axis. By binding to and activating PRs in the hypothalamus and pituitary gland, MPA exerts a strong negative feedback effect, inhibiting the pulsatile secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus. This, in turn, suppresses the release of pituitary gonadotropins: follicle-stimulating hormone (FSH) and, most critically, the mid-cycle surge of luteinizing hormone (LH).[3] The blunting of the LH surge is the central mechanism that prevents follicular maturation and ovulation, thereby providing a highly effective method of contraception.[3]

[Effects on Target Tissues]

In addition to its central effects on the HPG axis, MPA exerts significant local effects on the female reproductive tract, which contribute to its contraceptive and therapeutic efficacy.

• Endometrial Transformation: MPA transforms the proliferative endometrium (the uterine lining built up under the influence of estrogen) into a secretory state. With continuous, non-cyclic administration, as seen with depot injections, this progresses to endometrial thinning and atrophy. This atrophic endometrium is unreceptive and inhospitable to the implantation of a fertilized ovum, providing a secondary contraceptive mechanism.[2] This effect is also the basis for its use in treating endometriosis and abnormal uterine bleeding.
• Cervical Mucus Thickening: MPA increases the viscosity and reduces the quantity of cervical mucus. The resulting thick, scant mucus forms a formidable physical barrier that impairs the migration and penetration of sperm from the vagina into the upper reproductive tract, further reducing the likelihood of fertilization.[4]

Pharmacodynamics

[Hormonal Activity Spectrum]

MPA's pharmacodynamic profile is not limited to the progesterone receptor. While it is a potent progestin, it also exhibits weak but clinically meaningful activity at other steroid receptors, a property that distinguishes it from natural progesterone and some other synthetic progestins.

• Progestogenic Activity: This is its dominant and intended activity.
• Glucocorticoid Activity: MPA binds to the glucocorticoid receptor (GR) and acts as a partial to full agonist.[1] This activity is responsible for some of its unique side effects and therapeutic properties, such as its immunosuppressive effects.
• Androgenic Activity: MPA possesses weak androgenic activity, which can manifest clinically as side effects such as acne, hirsutism, and weight gain.[1]
• Estrogenic Activity: The drug is considered to be devoid of any significant estrogenic activity.[31]

This multi-receptor activity profile is a critical aspect of MPA's pharmacology. While its primary PR agonism drives its main therapeutic uses, its "off-target" interactions with the GR and androgen receptor are not merely pharmacological curiosities; they are the direct mechanistic basis for a significant portion of its clinical risk profile. The GR-mediated effects, for instance, are thought to contribute to metabolic disturbances like decreased glucose tolerance and are central to its immunosuppressive properties, which are not observed with natural progesterone.[6] This understanding provides a framework that links the drug's basic pharmacology directly to its clinical risk management.

[Antineoplastic and Anti-estrogenic Effects]

In the context of hormone-sensitive cancers, such as endometrial and renal carcinoma, MPA's efficacy arises from a combination of mechanisms. Its suppression of gonadotropin production leads to a decrease in endogenous estrogen secretion, depriving hormone-dependent tumors of a key growth stimulus.[6] Furthermore, MPA exerts direct anti-proliferative effects on tumor cells and reduces the expression of nuclear estrogen receptors and subsequent DNA synthesis within endometrial epithelial cells.[3] This potent anti-estrogenic effect on the endometrium is also the rationale for its use in MHT, where it counteracts the proliferative stimulus of estrogen, thereby preventing endometrial hyperplasia and cancer.[1]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of MPA is highly dependent on its route of administration, which dictates its absorption rate, bioavailability, and duration of action.

[Absorption]

• Oral Administration: Following oral administration, MPA is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations (Cmax​) achieved between 2 to 4 hours (Tmax​).[14] The bioavailability of oral MPA is significantly influenced by food. Administration with a meal can increase the Cmax​ by 50-70% and the total exposure (AUC) by 18-33%, although the half-life remains unchanged. This suggests that patients should be counseled to take the medication consistently with respect to meals to ensure predictable exposure.[14]
• Parenteral Administration (IM and SC): In stark contrast, parenteral administration of the microcrystalline suspension results in slow and prolonged absorption from the injection site depot. After a single 150 mg intramuscular dose of Depo-Provera, plasma concentrations increase for approximately 3 weeks to reach a Cmax​ of 1 to 7 ng/mL. The drug is then slowly released, with detectable concentrations persisting for 120 to 200 days, providing its long-acting contraceptive effect.[4]

[Distribution]

Once absorbed into the systemic circulation, MPA is extensively bound to plasma proteins, with approximately 86-90% bound primarily to albumin.[4] A key characteristic of its distribution is that it does not bind to sex hormone-binding globulin (SHBG), which distinguishes it from many endogenous and synthetic steroids and can influence the amount of free, active drug available to target tissues.[4]

[Metabolism]

MPA is extensively metabolized in the liver. The primary metabolic pathway is hydroxylation, which is mediated predominantly by the cytochrome P450 3A4 (CYP3A4) enzyme system. This initial step is followed by conjugation (e.g., with glucuronic acid) to form water-soluble metabolites.[4] More than 10 distinct metabolites have been identified.[4] This heavy reliance on CYP3A4 for clearance is the pharmacological basis for the most clinically significant drug-drug interactions associated with MPA. Co-administration with potent inducers of CYP3A4 (e.g., rifampin, carbamazepine, St. John's wort) can accelerate MPA metabolism, leading to lower plasma concentrations and potentially reduced contraceptive efficacy. Conversely, potent CYP3A4 inhibitors could increase MPA concentrations.[31]

[Excretion]

The metabolites of MPA are eliminated from the body primarily through the kidneys. Most are excreted in the urine as glucuronide conjugates, with only minor amounts appearing as sulfates.[4]

[Pharmacokinetics in Special Populations]

Given that MPA is almost exclusively eliminated via hepatic metabolism, its pharmacokinetics are significantly altered in patients with hepatic insufficiency. In individuals with advanced liver disease, the elimination of MPA is reduced, leading to higher and more prolonged exposure.[31] Consequently, MPA is contraindicated in patients with significant liver disease.[9] The impact of renal impairment on the pharmacokinetics of MPA has not been formally studied, but given its primary hepatic clearance, major dose adjustments are not typically considered necessary based on renal function alone.[4]

Clinical Applications and Therapeutic Efficacy

Medroxyprogesterone Acetate has a broad spectrum of clinical applications, reflecting its potent progestogenic and anti-estrogenic activities. Its use ranges from one of the most widely used long-acting contraceptives to a key component of menopausal hormone therapy and a palliative agent in advanced cancers.

Contraception

The primary and most common use of MPA is for long-acting, reversible contraception, delivered via depot injection.[1]

• Depot Medroxyprogesterone Acetate (DMPA-IM & DMPA-SC): The two main formulations are Depo-Provera, which contains 150 mg of MPA for deep intramuscular (IM) injection, and Depo-SubQ Provera 104, which contains a lower dose of 104 mg for subcutaneous (SC) injection.[1] Both are administered every 3 months (12 to 14 weeks).[38] DMPA is a highly effective contraceptive method, with a perfect-use failure rate of approximately 0.2% and a typical-use failure rate around 6% in the first year.[1]
• Advantages: The key advantages of DMPA include its high efficacy, long duration of action (obviating the need for daily adherence), and its estrogen-free nature. The absence of estrogen means it does not carry the increased risk of venous thromboembolism (VTE), stroke, or myocardial infarction associated with combined estrogen-progestin contraceptives, making it a suitable option for women with contraindications to estrogen.[1] It also has fewer significant drug interactions compared to oral contraceptives.[1]
• Non-Contraceptive Benefits: DMPA use is associated with several important non-contraceptive health benefits, including a profound reduction in the risk of endometrial cancer (by up to 80%), a decreased risk of pelvic inflammatory disease (PID), ectopic pregnancy, and iron-deficiency anemia due to reduced menstrual bleeding. It can also alleviate symptoms of endometriosis, dysmenorrhea, and ovulation pain.[1]
• Disadvantages: A significant disadvantage is the potential for a delayed return to fertility after discontinuation. Ovulation may not resume for 10 months or longer, making it an unsuitable choice for women planning a pregnancy in the near future.[32] It also does not offer protection against sexually transmitted infections (STIs).[32]

Menopausal Hormone Therapy

Oral MPA tablets, typically in low doses (e.g., 2.5 mg or 5 mg daily), are a cornerstone of combination menopausal hormone therapy (MHT) for postmenopausal women who have not undergone a hysterectomy.[1] In this context, the primary role of MPA is not to treat menopausal symptoms like hot flashes (which is the role of the estrogen component), but to protect the endometrium. Unopposed estrogen therapy in women with an intact uterus causes continuous proliferation of the uterine lining, which significantly increases the risk of endometrial hyperplasia and adenocarcinoma. MPA opposes this effect by inducing a secretory transformation and preventing overgrowth of the endometrium, thereby mitigating this cancer risk.[1]

Management of Gynecological and Menstrual Disorders

MPA is effective in treating a range of gynecological conditions driven by hormonal imbalances or the presence of ectopic endometrial tissue.

• Endometriosis: Both oral and injectable MPA are used to manage the pain associated with endometriosis, including dysmenorrhea (painful periods) and dyspareunia (painful intercourse). It works by suppressing ovarian function, which reduces estrogen levels and causes atrophy of the ectopic endometrial implants.[1] Depo-SubQ Provera 104 is specifically indicated for this purpose.[5]
• Abnormal Uterine Bleeding (AUB) and Secondary Amenorrhea: Short courses of oral MPA (e.g., 5 to 10 mg daily for 5 to 10 days) are used to manage AUB and secondary amenorrhea resulting from hormonal imbalances, such as anovulatory cycles. The treatment induces a secretory transformation of the estrogen-primed endometrium, and a predictable withdrawal bleed typically occurs within 3 to 7 days after the course of MPA is completed, effectively "restarting" the menstrual cycle.[1]

Oncological Indications

High-dose parenteral MPA (e.g., 400 to 1,000 mg IM weekly) serves as an adjunctive and palliative therapy for certain inoperable, recurrent, or metastatic hormone-dependent cancers.[1] Its antineoplastic effect is thought to result from both indirect hormonal suppression (via gonadotropin inhibition) and direct effects on tumor cells. Key indications include:

• Endometrial Carcinoma [5]
• Renal Cell Carcinoma [5]
• Breast Cancer (in post-menopausal women with recurrent, hormone-sensitive disease) [6]

Other Significant Clinical Uses (On- and Off-Label)

MPA's diverse pharmacological effects have led to its use in several other clinical scenarios.

• Management of Paraphilia and Hypersexuality: High-dose DMPA is used as a form of reversible chemical castration to reduce libido, sexual fantasies, and deviant sexual behaviors in males, including in the management of convicted sex offenders. It achieves this by potently suppressing the HPG axis, leading to a significant reduction in serum testosterone levels.[1]
• Appetite Stimulation in Cancer-Associated Cachexia: MPA is approved in Europe and used off-label in other regions as an appetite stimulant to counter the anorexia and weight loss (cachexia) associated with advanced cancer and AIDS.[1] While it effectively increases appetite and body weight, the weight gain is primarily due to an increase in fat mass, not lean body mass.[8]
• Other Niche Indications: Clinical evidence and observation suggest additional benefits. MPA has been noted to decrease the frequency of seizures in some women with epilepsy and to reduce the incidence and severity of vaso-occlusive crises in women with sickle-cell disease, an application currently under further investigation in clinical trials.[1]

Table 2: Summary of Medroxyprogesterone Acetate Formulations, Indications, and Typical Dosage Regimens

Formulation	Strength(s)	Indication(s)	Typical Dosage Regimen	Source(s)
Oral Tablet	2.5 mg, 5 mg, 10 mg	Secondary Amenorrhea, Abnormal Uterine Bleeding	5-10 mg daily for 5-10 days, starting on day 16 or 21 of the cycle.	33
		Endometrial Hyperplasia Prophylaxis (in MHT)	5-10 mg daily for 12-14 consecutive days per month.	35
IM Suspension	150 mg/mL	Contraception	150 mg IM every 3 months (13 weeks).	9
	400 mg/mL	Endometrial or Renal Carcinoma (Palliative)	400-1,000 mg IM weekly initially; may reduce to 400 mg monthly for maintenance.	33
		Paraphilia in Males (Unlabeled)	200 mg IM 2-3 times per week, or 500 mg IM weekly, adjusted to response.	5
SC Suspension	104 mg/0.65 mL	Contraception	104 mg SC every 3 months (12-14 weeks).	27
		Endometriosis-Associated Pain	104 mg SC every 3 months (12-14 weeks).	27

In-Depth Safety Profile and Risk Management

The therapeutic use of Medroxyprogesterone Acetate is intrinsically linked to a complex and significant safety profile. The risks range from common, manageable side effects to severe, life-threatening events that have prompted the highest level of warning from regulatory agencies. A thorough understanding of this profile is essential for appropriate patient selection, counseling, and monitoring.

FDA Boxed Warnings: A Detailed Analysis

The FDA has mandated Boxed Warnings for MPA, reflecting data on serious or life-threatening risks. These warnings differ based on the formulation and indication.

[Loss of Bone Mineral Density (BMD)]

This warning is specific to the long-acting injectable contraceptive formulations, Depo-Provera and Depo-SubQ Provera 104.[9]

• Pathophysiology and Risk: The use of DMPA is associated with a significant loss of bone mineral density. This effect is driven by the drug's suppression of gonadotropin secretion, which leads to a state of hypoestrogenism. Reduced estrogen levels disrupt the balance of bone remodeling, favoring resorption over formation, resulting in a net loss of bone mass.[41] The loss of BMD is greater with increasing duration of use and may not be completely reversible, even after discontinuation of the drug.[9]
• Vulnerable Populations: This risk is of particular concern for adolescents and young adults, as this is a critical period for bone accretion. The use of DMPA during these years may lead to a lower peak bone mass, which is a major risk factor for developing osteoporosis and fragility fractures later in life.[9]
• Regulatory Recommendation: Due to this significant risk, the FDA recommends that the use of DMPA for contraception or endometriosis treatment should not be continued for longer than two years unless other therapeutic or contraceptive options are considered inadequate.[11]

[Risks in Estrogen-Progestin Therapy]

This Boxed Warning applies to oral MPA when used in combination with estrogens as part of MHT and is based on findings from the Women's Health Initiative (WHI) study.[12] The warning explicitly states that estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. The WHI demonstrated that this combination therapy increases the risk of several serious conditions:

• Cardiovascular Disorders: The WHI estrogen plus progestin substudy reported a statistically significant increased risk of stroke and a 2-fold greater rate of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), in women receiving daily conjugated estrogens (CE) plus MPA compared to placebo.[5] The risk of coronary heart disease (CHD) was also non-significantly increased.[13]
• Invasive Breast Cancer: After a mean follow-up of 5.6 years, the WHI reported a statistically significant increased risk of invasive breast cancer in women taking CE plus MPA compared to placebo.[5]
• Probable Dementia: An ancillary study of the WHI, the WHI Memory Study (WHIMS), found that in women aged 65 years and older, treatment with CE plus MPA was associated with a 2-fold increased risk of developing probable dementia compared to placebo.[14]

Common and Significant Adverse Effects

Beyond the boxed warnings, MPA is associated with a wide range of adverse effects.

• Most Common (>5% Incidence): The most frequently reported adverse effects are related to its potent hormonal activity. Menstrual irregularities—including irregular bleeding, spotting, heavy bleeding, or amenorrhea (cessation of periods)—are extremely common, affecting up to 57% of users in the first year of contraceptive use.[1] Weight gain is also a very common side effect, with studies showing a mean gain of 5 pounds after one year and up to 38% of users gaining more than 10 pounds by 24 months.[9] Other common adverse reactions include headache (up to 17%), abdominal pain/discomfort (11%), nervousness (11%), dizziness (6%), and decreased libido (6%).[9]
• System-Organ Class Review: Other clinically significant adverse effects include psychiatric disturbances such as depression, anxiety, and irritability; dermatologic effects like acne, rash, alopecia, and hirsutism; metabolic changes including fluid retention and decreased glucose tolerance; and gastrointestinal symptoms such as nausea and bloating.[6]

Emerging Risk: Intracranial Meningioma

A significant and contemporary safety concern has emerged regarding the risk of intracranial meningioma with prolonged MPA use.

• Review of Epidemiological Evidence: A large, nationwide case-control study from France, published in The BMJ in March 2024, provided strong evidence for this association. The study analyzed data from over 18,000 women who underwent surgery for meningioma and found that prolonged use (defined as one year or more) of injectable MPA was associated with a 5.6-fold increased risk of developing the tumor (odds ratio 5.55).[15] Subsequent studies, including one using a U.S. Medicaid database, have corroborated these findings, demonstrating a similarly elevated risk with prolonged dMPA use (OR ranging from 4.01 to 5.40) when compared to both active (other hormonal contraceptives) and non-active controls.[61] The biological plausibility for this link is strong, as a majority of meningiomas express progesterone receptors, suggesting they can be stimulated by progestogenic agents.[61]
• Regulatory Response: In light of this compelling new evidence, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) issued new safety recommendations in late 2024. The committee recommended that high-dose MPA (injectables and tablets ≥100 mg) be contraindicated for non-oncological indications in patients with a current or past meningioma. They also advised that patients receiving high-dose MPA should be monitored for symptoms of meningioma, such as vision changes, hearing loss, headaches, or seizures.[16]
• Clinical and Legal Implications: This emerging risk fundamentally alters the risk-benefit discussion for long-term MPA users. It necessitates updated patient counseling and informed consent practices. The findings have also prompted legal action against the manufacturer, alleging failure to adequately warn of this risk.[15]

Contraindications and High-Risk Populations

Based on its known risks, MPA is absolutely contraindicated in individuals with the following conditions [9]:

• Known or suspected pregnancy
• Active thrombophlebitis, or a current or past history of thromboembolic disorders (DVT, PE) or cerebrovascular disease
• Known or suspected malignancy of the breast
• Significant liver disease or dysfunction
• Undiagnosed vaginal bleeding
• Known hypersensitivity to MPA or its components

Immunosuppressive and Neurobiological Considerations

MPA's pharmacology extends beyond its effects on the reproductive system, with important implications for the immune and central nervous systems.

• Glucocorticoid Receptor-Mediated Immunosuppression: A critical distinction between MPA and natural progesterone is MPA's ability to bind to and activate the glucocorticoid receptor (GR) with relatively high affinity.[18] This GR-mediated activity imparts potent immunosuppressive properties to MPA, including the suppression of T-cell function and the inhibition of pro-inflammatory cytokine production (e.g., IL-2, IFN-γ).[18] This mechanism provides a unifying explanation for several of MPA's distinct risks. The same GR activation that is responsible for its immunosuppressive effects is also a known driver of bone density loss and can lead to metabolic side effects like hyperglycemia and insulin resistance, which are classic effects of glucocorticoids.[6] This GR activity has raised concerns about a potential increase in susceptibility to STIs, including HIV, which prompted the large-scale ECHO clinical trial. While that trial did not find a substantial difference in HIV acquisition risk among users of DMPA, an LNG implant, or a copper IUD, the underlying biological questions about mucosal immunity remain an area of active research.[70]
• Antagonism of Estrogen's Neuroprotective Effects: Preclinical research has demonstrated another important divergence from natural hormones. While both estrogen and natural progesterone can exert neuroprotective effects against excitotoxicity, MPA appears to antagonize these benefits. Studies in hippocampal neurons have shown that MPA can completely block the ability of estrogen to attenuate the glutamate-induced rise in intracellular calcium, a key event in neuronal cell death.[72] This finding may provide a mechanistic underpinning for the increased risk of dementia observed in the WHIMS trial with combined estrogen-MPA therapy.

Historical Context and Commercial Landscape

The trajectory of Medroxyprogesterone Acetate from its synthesis to its current global use has been marked by scientific innovation, significant controversy, and evolving regulatory oversight.

Development and Regulatory History

Medroxyprogesterone Acetate was first synthesized in 1954 by scientists at the Upjohn Company, which, through a series of mergers and acquisitions, is now part of Pfizer.[15] It was introduced for medical use in the United States in 1959.[1] While its use for gynecological disorders and in oncology was established relatively early, its path to approval as a contraceptive in the U.S. was notably prolonged and contentious.

During the 1960s and 1970s, clinical trials for its contraceptive use (as Depo-Provera) were conducted, but these were later criticized for ethical lapses, including the targeting of vulnerable populations and allegations of inadequate informed consent regarding the drug's risks and side effects.[15] Citing long-term safety concerns, particularly a potential risk of cancer based on animal studies, the U.S. FDA rejected the application for Depo-Provera as a contraceptive in 1974. Despite this rejection, it was approved and widely used for contraception in many other countries. Following additional studies and considerable debate, the FDA finally approved Depo-Provera for contraceptive use in the United States in 1992, nearly two decades after its initial rejection.[15] This history of controversy underscores the long-standing debate surrounding the drug's complex risk-benefit profile.

Global Market Presence

Today, MPA is a widely prescribed medication globally and is included on the World Health Organization's List of Essential Medicines.[73] In 2022, it was the 276th most commonly prescribed medication in the United States, with over 800,000 prescriptions filled.[1]

[Major Brand Names and Formulations]

MPA is marketed under numerous brand names worldwide, with the most globally recognized being those from the originator, Pfizer:

• Provera®: The brand name for oral tablets.[6]
• Depo-Provera®: The brand name for the 150 mg/mL intramuscular contraceptive injection.[1]
• Depo-SubQ Provera 104®: The brand name for the 104 mg/0.65 mL subcutaneous contraceptive injection.[1]

Other brand names available in the U.S. and internationally include Amen®, Curretab®, Cycrin®, Sayana Press®, and Climanor®.[21] It is also a component of combination MHT products such as Prempro® and Premphase®.[21] A wide array of other brand names exist in various international markets, including Farlutal®, Gestapuran®, and Perlutex®.[76]

[Key Manufacturers of Finished Products and Active Pharmaceutical Ingredient (API)]

• Originator and Brand Manufacturer: Pfizer Inc. remains the primary manufacturer of the branded Provera and Depo-Provera products.[15]
• Generic Finished Product Manufacturers: With the expiration of key patents, a robust generic market has developed. Major manufacturers of generic MPA finished dosage forms (tablets and injectables) include Teva Pharmaceutical Industries, Amneal Pharmaceuticals, Amphastar Pharmaceuticals, Eugia Pharma, Sandoz, and Sun Pharmaceutical Industries.[82]
• Active Pharmaceutical Ingredient (API) Suppliers: A separate global network of chemical and pharmaceutical companies manufactures the bulk MPA active ingredient for formulation by other companies. Prominent API suppliers with regulatory filings (e.g., Drug Master Files) in major markets include Axplora (via its subsidiary Farmabios), Coral Drugs, Zhejiang Xianju Pharmaceutical, KRKA, and Jiangsu Jiaerke Pharmaceuticals, among many others across Europe, Asia, and North America.[81]

Future Directions and Ongoing Research

The clinical landscape for Medroxyprogesterone Acetate continues to be shaped by ongoing research aimed at optimizing its use, expanding its therapeutic applications, and further clarifying its long-term safety profile. Current clinical trials and recent research findings point toward several key areas of development and investigation.

Novel Formulations and Indications

A significant focus of current research is on improving patient convenience and adherence through the development of longer-acting formulations. A large, multi-clinic, ongoing clinical trial (ISRCTN62695528) is actively evaluating the contraceptive efficacy, safety, and user satisfaction of a 6-month subcutaneous DMPA injection. This study aims to determine if a less frequent dosing schedule (twice yearly instead of four times) can provide the same level of contraceptive protection and safety as the current 3-month formulation. If successful, a 6-month product could represent a major advancement in long-acting reversible contraception.[94]

Beyond contraception, researchers are exploring the non-contraceptive benefits of MPA in specific patient populations. Building on earlier observations that DMPA may reduce the frequency of sickle cell crises, a new clinical trial (NCT06665997) was initiated to formally investigate whether DMPA can reduce vaso-occlusive pain episodes in women with sickle cell disease. This study will assess pain outcomes and a range of hematological and inflammatory biomarkers to elucidate the potential mechanism of this effect.[1] Other completed or ongoing trials have explored the pharmacokinetics of various MPA formulations, its use in combination with other hormones for contraception (NCT01699022), and its role in fertility-sparing treatment for early-stage endometrial cancer (NCT01594879).[95]

Evolving Risk-Benefit Profile

The future use of MPA will be heavily influenced by the ongoing re-evaluation of its risk-benefit profile in light of new safety data. The recent, compelling evidence linking long-term injectable MPA use to a significantly increased risk of intracranial meningioma will undoubtedly be a major driver of future research.[15] Further pharmacoepidemiological studies will be needed to more precisely define this risk across different populations, durations of use, and dosages, and to investigate whether the risk is associated with specific meningioma subtypes.

Similarly, while the large-scale ECHO trial (NCT02550067) provided reassuring evidence that DMPA does not substantially increase the risk of HIV acquisition compared to other effective contraceptive methods, the underlying questions about its immunosuppressive effects on mucosal biology persist.[70] Future research will likely continue to explore the complex interactions between MPA, the glucocorticoid receptor, and the genital tract immune environment.

Collectively, this body of research suggests a future where the use of MPA may become more stratified. There will be a continued effort to leverage its benefits in novel ways, such as in sickle cell disease, while simultaneously working to mitigate its risks by developing longer-acting formulations that may reduce cumulative exposure, better identifying patients most susceptible to its adverse effects, and potentially exploring alternative progestins with more favorable safety profiles for long-term use.[34]

Conclusion and Expert Recommendations

Medroxyprogesterone Acetate is a pharmacologically complex and clinically versatile synthetic progestin that has been a mainstay of hormonal therapy for over six decades. Its well-established efficacy in long-acting contraception, as a critical component of menopausal hormone therapy, in the management of gynecological disorders, and as a palliative agent in oncology underscores its significant therapeutic value. However, the use of MPA is inextricably linked to a substantial and evolving safety profile that demands careful and continuous risk-benefit assessment by clinicians and patients.

The molecule's unique pharmacological signature, characterized by potent progestogenic activity combined with clinically relevant glucocorticoid and androgenic effects, distinguishes it from natural progesterone and is mechanistically linked to many of its most serious adverse effects. The glucocorticoid receptor-mediated actions, in particular, appear to be a central driver of its potential for immunosuppression, metabolic disturbances, and, most notably, the significant loss of bone mineral density that prompted an FDA Boxed Warning. Further Boxed Warnings, derived from the landmark Women's Health Initiative, highlight the increased risk of cardiovascular events, breast cancer, and probable dementia when MPA is used in combination with estrogen for MHT. The recent emergence of strong evidence linking long-term injectable MPA use to a five-fold increased risk of intracranial meningioma represents a major addition to this risk profile, necessitating a paradigm shift in patient counseling and long-term prescribing practices.

In light of this comprehensive analysis, the following recommendations are provided for clinical practice:

1. Informed Consent is Paramount: The cornerstone of safe MPA prescribing is a thorough and transparent informed consent process. Clinicians must conduct a comprehensive discussion of the drug's complex risk-benefit profile, explicitly covering the FDA's Boxed Warnings regarding bone density loss and the risks of combination MHT. Crucially, this discussion must now include the new, dose- and duration-dependent risk of intracranial meningioma. Patients should be made aware of the early symptoms of meningioma (e.g., changes in vision or hearing, new persistent headaches, seizures) and instructed to report them promptly.
2. Adhere to Recommendations for Limiting Long-Term Use: In accordance with FDA guidance, the use of injectable MPA for contraception or endometriosis should generally be limited to two years unless other methods are deemed inadequate or unacceptable by the patient. For all indications, the continued need for therapy should be reassessed on a regular basis.
3. Implement Rigorous Patient Screening and Monitoring: Prior to initiation, all patients must be carefully screened for absolute contraindications, including a personal or strong family history of breast cancer, a history of venous thromboembolism, significant liver disease, and undiagnosed vaginal bleeding. For women who use MPA long-term, particularly those with other risk factors for osteoporosis (e.g., family history, low body weight, chronic steroid use), baseline and periodic bone mineral density monitoring should be strongly considered.
4. Consider Alternative Progestins for High-Risk Patients: For patients with significant pre-existing risk factors for MPA's specific adverse effects, clinicians should consider alternative progestins that have different receptor binding profiles. For example, progestins such as norethisterone or levonorgestrel, which lack the significant glucocorticoid activity of MPA, may represent safer alternatives for women with concerns about bone health or immunosuppression.[34]
5. Maintain Ongoing Pharmacovigilance: The medical community must remain vigilant for new safety signals associated with MPA. As demonstrated by recent analyses of post-marketing adverse event databases, real-world evidence continues to be critical for identifying both known and unexpected adverse drug reactions, ensuring that the understanding of MPA's safety profile remains current and comprehensive.[58]

Ultimately, Medroxyprogesterone Acetate remains an important therapeutic agent, but its potent hormonal effects necessitate a highly individualized and cautious approach to its use, grounded in a deep understanding of its evolving pharmacology and risks.

Works cited

1. Medroxyprogesterone acetate - Wikipedia, accessed August 18, 2025, https://en.wikipedia.org/wiki/Medroxyprogesterone_acetate
2. Medroxyprogesterone acetate: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 18, 2025, https://go.drugbank.com/drugs/DB00603
3. go.drugbank.com, accessed August 18, 2025, https://go.drugbank.com/drugs/DB00603#:~:text=Medroxyprogesterone%20acetate%20(MPA)%20inhibits%20the,it's%20ability%20to%20prevent%20pregnancy.&text=This%20action%20also%20thins%20the%20endometrium.&text=MPA%20reduces%20nuclear%20estrogen%20receptors,epithelial%20cells%20of%20the%20endometrium.
4. DEPO-PROVERA® CI (medroxyprogesterone acetate injectable suspension, for intramuscular use) Clinical Pharmacology | Pfizer Medical - US, accessed August 18, 2025, https://www.pfizermedical.com/depo-provera/clinical-pharmacology
5. Medroxyprogesterone: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed August 18, 2025, https://www.medcentral.com/drugs/monograph/63866-382470/medroxyprogesterone-intramuscular
6. Medroxyprogesterone acetate (Provera) | Side effects - Cancer Research UK, accessed August 18, 2025, https://www.cancerresearchuk.org/about-cancer/treatment/drugs/medroxyprogesterone
7. jaapl.org, accessed August 18, 2025, https://jaapl.org/content/jaapl/23/1/19.full.pdf
8. Medroxyprogesterone acetate in the management of cancer cachexia - ResearchGate, accessed August 18, 2025, https://www.researchgate.net/publication/24430541_Medroxyprogesterone_acetate_in_the_management_of_cancer_cachexia
9. Medroxyprogesterone Injection ER: Package Insert / Prescribing Info - Drugs.com, accessed August 18, 2025, https://www.drugs.com/pro/medroxyprogesterone-injection-er.html
10. Medroxyprogesterone Injection: Side Effects, Dosage, and More - Healthline, accessed August 18, 2025, https://www.healthline.com/health/drugs/medroxyprogesterone-injectable-suspension
11. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights ..., accessed August 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021583s033s034lbl.pdf
12. www.pfizermedical.com, accessed August 18, 2025, https://www.pfizermedical.com/provera/boxed-warning#:~:text=Boxed%20Warning-,WARNING%3A%20CARDIOVASCULAR%20DISORDERS%2C%20BREAST%20CANCER%20AND%20PROBABLE%20DEMENTIA,FOR%20ESTROGEN%20PLUS%20PROGESTIN%20THERAPY
13. PROVERA® (medroxyprogesterone acetate) Warnings and Precautions | Pfizer Medical, accessed August 18, 2025, https://www.pfizermedical.com/provera/warnings
14. PROVERA® (medroxyprogesterone acetate tablets, USP) WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR - accessdata.fda.gov, accessed August 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/011839s083lbl.pdf
15. A Guide to the History of Depo-Provera | Anapol Weiss, accessed August 18, 2025, https://www.anapolweiss.com/blog/a-guide-to-the-history-of-depo-provera/
16. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 September 2024 | European Medicines Agency (EMA), accessed August 18, 2025, https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-2-5-september-2024
17. Use of progestogens and the risk of intracranial meningioma: national case-control study | The BMJ, accessed August 18, 2025, https://www.bmj.com/content/384/bmj-2023-078078
18. Dissociative Glucocorticoid Activity of Medroxyprogesterone Acetate in Normal Human Lymphocytes1 - Oxford Academic, accessed August 18, 2025, https://academic.oup.com/jcem/article/84/11/4055/2864492
19. Immunosuppressive Biological Mechanisms Support Reassessment of Use of the Injectable Contraceptive Medroxyprogesterone Acetate | Endocrinology | Oxford Academic, accessed August 18, 2025, https://academic.oup.com/endo/article/154/3/985/2423272
20. Medroxyprogesterone Acetate | C24H34O4 | CID 6279 - PubChem, accessed August 18, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Medroxyprogesterone-Acetate
21. Medroxyprogesterone - brand name list from Drugs.com, accessed August 18, 2025, https://www.drugs.com/ingredient/medroxyprogesterone.html
22. Medroxyprogesterone 17-acetate = 97 HPLC 71-58-9 - Sigma-Aldrich, accessed August 18, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/m1629
23. PROVERA® (medroxyprogesterone acetate tablets, USP) WARNINGS CARDIOVASCULAR AND OTHER RISKS - accessdata.fda.gov, accessed August 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf
24. depo-subQ provera 104® medroxyprogesterone acetate injectable suspension 104 mg/0.65 mL - accessdata.fda.gov, accessed August 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021583s025lbl.pdf
25. Medroxyprogesterone Acetate 71-58-9 | Tokyo Chemical Industry Co., Ltd.(APAC), accessed August 18, 2025, https://www.tcichemicals.com/OP/en/p/M1964
26. Depo-Provera - accessdata.fda.gov, accessed August 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/012541s086lbl.pdf
27. depo-subq provera 104 - accessdata.fda.gov, accessed August 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021583s043lbl.pdf
28. Pharmacology of Progestin Injection; Medroxyprogesterone Acetate (Depo provera); Mechanism of Action - YouTube, accessed August 18, 2025, https://www.youtube.com/watch?v=gx3CxRBqNAw
29. Medroxyprogesterone | C22H32O3 | CID 10631 - PubChem, accessed August 18, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/10631
30. Medroxyprogesterone - StatPearls - NCBI Bookshelf, accessed August 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK559192/
31. PROVERA® (medroxyprogesterone acetate) Clinical Pharmacology ..., accessed August 18, 2025, https://www.pfizermedical.com/provera/clinical-pharmacology
32. Depo-Provera (birth control shot) - Mayo Clinic, accessed August 18, 2025, https://www.mayoclinic.org/tests-procedures/depo-provera/about/pac-20392204
33. medroxyprogesterone acetate, accessed August 18, 2025, https://m.glowm.com/resources/glowm/cd/pages/drugs/m011.html
34. Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs - PMC, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4874781/
35. Medroxyprogesterone Uses, Dosage & Side Effects - Drugs.com, accessed August 18, 2025, https://www.drugs.com/medroxyprogesterone.html
36. DEPO-PROVERA® CI (medroxyprogesterone acetate injectable suspension, for intramuscular use) Drug Interactions | Pfizer Medical - US, accessed August 18, 2025, https://www.pfizermedical.com/depo-provera/drug-interactions
37. DEPO-SUBQ PROVERA 104® (medroxyprogesterone acetate) Drug Interactions | Pfizer Medical - US, accessed August 18, 2025, https://www.pfizermedical.com/depo-subq-provera-104/drug-interactions
38. Medroxyprogesterone Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 18, 2025, https://www.drugs.com/dosage/medroxyprogesterone.html
39. MEDROXYPROGESTERONE acetate injectable - MSF Medical Guidelines, accessed August 18, 2025, https://medicalguidelines.msf.org/en/viewport/EssDr/english/medroxyprogesterone-acetate-injectable-16682904.html
40. PROVERA® (medroxyprogesterone acetate) Clinical Studies | Pfizer Medical - US, accessed August 18, 2025, https://www.pfizermedical.com/provera/clinical-studies
41. Depo-Provera - Pfizer, accessed August 18, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=12215
42. What is the dosing for Depo-Provera (medroxyprogesterone acetate) for libido reduction in males with intellectual disability and paraphilic disorders? - Dr.Oracle AI, accessed August 18, 2025, https://www.droracle.ai/articles/95648/what-is-the-dosing-for-depo-provera-for-males-that-need-their-libido-decreased-because-of-intellectual-disability-and-sexual-deviance
43. Low-dose oral medroxyprogesterone acetate in the management of the paraphilias - PubMed, accessed August 18, 2025, https://pubmed.ncbi.nlm.nih.gov/8509348/
44. Treatment of sex offenders with medroxyprogesterone acetate - Psychiatry Online, accessed August 18, 2025, https://psychiatryonline.org/doi/10.1176/ajp.138.5.644
45. Treatment of Paraphilic Disorder Using Medroxyprogesterone Acetate - ResearchGate, accessed August 18, 2025, https://www.researchgate.net/publication/375633724_Treatment_of_Paraphilic_Disorder_Using_Medroxyprogesterone_Acetate
46. Medroxyprogesterone acetate in the management of cancer cachexia - PubMed, accessed August 18, 2025, https://pubmed.ncbi.nlm.nih.gov/19445562/
47. Medroxyprogesterone acetate (Provera®) - Macmillan Cancer Support, accessed August 18, 2025, https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/medroxyprosterone-acetate
48. Medicines for diet problems - Cancer Research UK, accessed August 18, 2025, https://www.cancerresearchuk.org/about-cancer/coping/physically/diet-problems/managing/medicines-for-diet-problems
49. MEGESTROL ACETATE IN CANCER PATIENTS WITH ANOREXIA AND WEIGHT LOSS, accessed August 18, 2025, https://medicaljournalssweden.se/actaoncologica/article/download/31760/36660/85481
50. Megestrol acetate (MEGACE) and medroxyprogesterone (MPA) as appetite stimulants, accessed August 18, 2025, https://primarycarenotebook.com/pages/cardiovascular-medicine/megestrol-acetate-megace-and-medroxyprogesterone-mpa-as-appetite-stimulants
51. Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease | ClinicalTrials.gov, accessed August 18, 2025, https://clinicaltrials.gov/study/NCT06665997
52. DEPO-PROVERA® CI (medroxyprogesterone acetate injectable suspension, for intramuscular use) Clinical Studies | Pfizer Medical Information - US, accessed August 18, 2025, https://www.pfizermedicalinformation.com/depo-provera/clinical-studies
53. Label: MEDROXYPROGESTERONE ACETATE injection, suspension - DailyMed, accessed August 18, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01e28bef-9758-40cf-a4ff-86ae9f4f5105
54. Annotation of FDA Label for medroxyprogesterone and ESR1, ESR2 - PharmGKB, accessed August 18, 2025, https://www.clinpgx.org/labelAnnotation/PA166353121
55. Medroxyprogesterone Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 18, 2025, https://www.drugs.com/sfx/medroxyprogesterone-side-effects.html
56. Depo-Provera® (Birth Control Shot): Risks & Benefits - Cleveland Clinic, accessed August 18, 2025, https://my.clevelandclinic.org/health/drugs/4086-depo-provera-birth-control-shot
57. Side effects of medroxyprogesterone tablets - NHS, accessed August 18, 2025, https://www.nhs.uk/medicines/medroxyprogesterone-tablets/side-effects-of-medroxyprogesterone-tablets/
58. Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data - Frontiers, accessed August 18, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1491032/full
59. Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data - PMC, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11701781/
60. Use of progestogens and the risk of intracranial meningioma: national case-control study, accessed August 18, 2025, https://pubmed.ncbi.nlm.nih.gov/38537944/
61. The Relationship Between Medroxyprogesterone Acetate and Intracranial Meningioma: A Review of Current Evidence and Recommendations for Future Study - Alexa Letizia, accessed August 18, 2025, https://alexaletizia.journoportfolio.com/articles/the-relationship-between-medroxyprogesterone-acetate-and-intracranial-meningioma-a-review-of-current-evidence-and-recommendations-for-future-study/
62. A Matched Case-Control Study Examining the Association Between Exposure to Depot Medroxyprogesterone Acetate and Cerebral Meningioma Using an Active Comparator - MDPI, accessed August 18, 2025, https://www.mdpi.com/1718-7729/32/7/401
63. Depo-Provera Linked to Increased Risk of Brain Tumors [2025 Update] | King Law, accessed August 18, 2025, https://www.robertkinglawfirm.com/personal-injury/depo-provera-lawsuit/depo-provera-and-brain-tumors/
64. The association between medroxyprogesterone acetate exposure and cerebral meningioma among a Medicaid population | medRxiv, accessed August 18, 2025, https://www.medrxiv.org/content/10.1101/2025.06.26.25330350v1.full-text
65. The association between medroxyprogesterone acetate exposure and cerebral meningioma among a Medicaid population - medRxiv, accessed August 18, 2025, https://www.medrxiv.org/content/10.1101/2025.06.26.25330350v1.full.pdf
66. Medroxyprogesterone acetate - direct healthcare professional communication (DHPC) | European Medicines Agency (EMA), accessed August 18, 2025, https://www.ema.europa.eu/en/medicines/dhpc/medroxyprogesterone-acetate
67. www.ncbi.nlm.nih.gov, accessed August 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK559192/#:~:text=Medroxyprogesterone%20injections%20are%20contraindicated%20in,disease%2C%20and%20arterial%20vascular%20disease.
68. The Antiinflammatory Properties of Medroxyprogesterone Acetate | Circulation, accessed August 18, 2025, https://www.ahajournals.org/doi/10.1161/01.CIR.0000037450.70394.95
69. Medroxyprogesterone Acetate Decreases Th1, Th17, and Increases Th22 Responses via AHR Signaling Which Could Affect Susceptibility to Infections and Inflammatory Disease - Frontiers, accessed August 18, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.00642/full
70. An updated review on the effects of depot medroxyprogesterone acetate on the mucosal biology of the female genital tract - PubMed Central, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8459266/
71. The Evidence for Contraceptive Options and HIV Outcomes Trial (ECHO) - ClinicalTrials.gov, accessed August 18, 2025, https://clinicaltrials.gov/study/NCT02550067
72. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling | PNAS, accessed August 18, 2025, https://www.pnas.org/doi/10.1073/pnas.1334098100
73. en.wikipedia.org, accessed August 18, 2025, https://en.wikipedia.org/wiki/Medroxyprogesterone_acetate#:~:text=MPA%20was%20discovered%20in%201956,in%20progestogen%2Donly%20birth%20control.
74. Medroxyprogesterone tablets: medicine for hormone conditions - NHS, accessed August 18, 2025, https://www.nhs.uk/medicines/medroxyprogesterone-tablets/
75. About medroxyprogesterone contraceptive injections - NHS, accessed August 18, 2025, https://www.nhs.uk/medicines/contraceptive-injections-medroxyprogesterone/about-medroxyprogesterone-contraceptive-injections/
76. Definition of medroxyprogesterone acetate - NCI Drug Dictionary - NCI, accessed August 18, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/medroxyprogesterone-acetate
77. Medroxyprogesterone (oral route) - Side effects & dosage - Mayo Clinic, accessed August 18, 2025, https://www.mayoclinic.org/drugs-supplements/medroxyprogesterone-oral-route/description/drg-20146771
78. PROVERA (medroxyprogesterone acetate USP) - Pfizer Canada, accessed August 18, 2025, https://www.pfizer.ca/en/our-products/provera-medroxyprogesterone-acetate-usp
79. Medroxyprogesterone - Drug Usage Statistics, ClinCalc DrugStats Database, accessed August 18, 2025, https://clincalc.com/DrugStats/Drugs/Medroxyprogesterone
80. Medroxyprogesterone Acetate (Tablet) Available Brands - MedEx, accessed August 18, 2025, https://medex.com.bd/generics/1835/medroxyprogesterone-acetate-tablet/brand-names
81. Medroxyprogesterone Acetate | 71-58-9 - ChemicalBook, accessed August 18, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8130110.htm
82. Generic MEDROXYPROGESTERONE ACETATE INN entry, pharmaceutical patent expiry and freedom to operate - DrugPatentWatch, accessed August 18, 2025, https://www.drugpatentwatch.com/p/generic-api/MEDROXYPROGESTERONE+ACETATE
83. Generic Depo Provera Availability - Drugs.com, accessed August 18, 2025, https://www.drugs.com/availability/generic-depo-provera.html
84. Depo-Provera Contraceptive: Package Insert / Prescribing Info, accessed August 18, 2025, https://www.drugs.com/pro/depo-provera.html
85. Medroxyprogesterone Acetate Tablets, USP - USA - Teva Pharmaceuticals, accessed August 18, 2025, https://www.tevausa.com/our-products/tevagenerics/teva-generics-catalog/vision-product-page/medroxyprogesteroneacetatetabletsusp
86. Medroxyprogesterone Acetate - Axplora, accessed August 18, 2025, https://www.axplora.com/api-product/71-58-9-s/
87. Medroxyprogesterone acetate API Manufacturers & Suppliers - Pharmaoffer.com, accessed August 18, 2025, https://pharmaoffer.com/api-excipient-supplier/progestagens/medroxyprogesterone-acetate
88. Medroxyprogesterone Acetate - LGM Pharma, accessed August 18, 2025, https://lgmpharma.com/product/medroxyprogesterone-acetate/
89. Medroxyprogesterone Acetate | progesterone receptor agonist | Buy from Supplier AdooQ®, accessed August 18, 2025, https://www.adooq.com/medroxyprogesterone-acetate.html
90. Medroxyprogesterone Acetate, USP (Micro) | API - Medisca, accessed August 18, 2025, https://www.medisca.com/products/medroxyprogesterone-acetate-usp-micro
91. Medroxyprogesterone 17-acetate | Manufacturers | Suppliers | India - Manus Aktteva Biopharma LLP, accessed August 18, 2025, https://www.manusaktteva.com/api/Medroxyprogesterone+17-acetate
92. Medroxyprogesterone Acetate API Manufacturers | Suppliers - PharmaCompass.com, accessed August 18, 2025, https://www.pharmacompass.com/listed-active-pharmaceutical-ingredients/medroxyprogesterone-acetate
93. FDA-Approved Progesterone API Manufacturers & Suppliers - Pharmaoffer.com, accessed August 18, 2025, https://pharmaoffer.com/api-excipient-supplier/progestagens/progesterone/fda
94. ISRCTN62695528: A large, multi-clinic study to evaluate contraceptive efficacy and safety of depot medroxyprogesterone acetate (150 mg/ml) injected under the skin every 6 months - ISRCTN Registry, accessed August 18, 2025, https://www.isrctn.com/ISRCTN62695528
95. Treatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer | ClinicalTrials.gov, accessed August 18, 2025, https://clinicaltrials.gov/study/NCT01594879
96. Pharmacokinetic and Pharmacodynamic Study of Cyclofem - ClinicalTrials.gov, accessed August 18, 2025, https://clinicaltrials.gov/study/NCT01699022
97. Medroxyprogesterone Acetate Research Articles - R Discovery, accessed August 18, 2025, https://discovery.researcher.life/topic/depo-medroxyprogesterone/3128318?page=1&topic_name=Depo%20Medroxyprogesterone
98. Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system - ResearchGate, accessed August 18, 2025, https://www.researchgate.net/publication/388562271_Data_pharmacovigilance_analysis_of_medroxyprogesterone-related_adverse_events_in_the_FDA_adverse_event_reporting_system